Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Open-Label Study to Assess the Safety and Efficacy of AlloStim® + Anti-PDL1 as Fourth Line Therapy for MSS Metastatic Colorectal Cancer

Next Previous
Search
Trial Profile

Phase II Open-Label Study to Assess the Safety and Efficacy of AlloStim® + Anti-PDL1 as Fourth Line Therapy for MSS Metastatic Colorectal Cancer

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; T-cell vaccine-AlloStim (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms COMMUNITY
  • Sponsors Mirror Biologics

    • Most Recent Events

    • 08 Jan 2025 According to a Mirror Biologics media release, the company has entered into a clinical collaboration with Merck KGaA, Darmstadt, Germany to conduct this Phase II clinical trial to evaluate the combination of an experimental immunotherapy drug, AlloStim from Mirror, and an immune checkpoint inhibitor (ICI), avelumab (BAVENCIO) from Merck KGaA, Darmstadt, Germany, in fourth-line metastatic colorectal cancer.
    • 27 Sep 2024 Planned End Date changed from 1 Mar 2026 to 1 Nov 2025.
    • 27 Sep 2024 Planned primary completion date changed from 1 Mar 2026 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top